CD4+ T cell depletion at early time points abrogated vaccine efficacy, whereas late depletion aided E743–77-pulsed mBMDC vaccine efficacy at later time points and enhanced tumor control and CD8+ T cell responses (Figure 5, F, I, and J). The gene discussed is CD8A; the disease is neoplasm.